A lethal pneumonia model of Acinetobacter baumannii: an investigation in immunocompetent mice

X Zeng1, H Gu1, Y Cheng2

  • 1National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, China.

Abstract

Insights

A new lethal pneumonia model in immunocompetent mice was developed using the hypervirulent Acinetobacter baumannii isolate SJZ24. This model is effective for studying immune responses and evaluating vaccines against A. baumannii infections.

Area of Science:

  • Microbiology
  • Immunology
  • Pathogenesis

Background:

  • Acinetobacter baumannii causes severe pneumonia, necessitating effective mouse models for research.
  • Existing models are often non-lethal or require immunosuppression, limiting their utility for studying host immunity and therapies.

Purpose of the Study:

  • To establish a lethal pneumonia model in immunocompetent mice using a hypervirulent A. baumannii isolate.
  • To evaluate the utility of this model for studying host immune responses and assessing vaccine efficacy.

Main Methods:

  • Assessed virulence of 30 clinical A. baumannii isolates in mice.
  • Selected the most virulent isolate, SJZ24, for model development.
  • Analyzed cytokine mRNA expression, bronchoalveolar lavage fluid cell infiltration, and vaccine efficacy.

Main Results:

  • Intratracheal inoculation with SJZ24 (5 × 10^7 CFU) caused 100% mortality in immunocompetent mice.
  • Infected mice exhibited high bacterial loads, organ damage, lung inflammation, and neutrophil infiltration.
  • Vaccination with inactivated SJZ24 provided 100% protection against lethal infection.

Conclusions:

  • A lethal pneumonia model in immunocompetent mice was successfully established using A. baumannii SJZ24.
  • This model is suitable for investigating the immune response to A. baumannii and evaluating potential vaccines.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
882
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
18.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
887
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.9K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
812
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.5K